CASI Pharmaceuticals, Inc. CASI Cash Flow

Casi pharmaceuticals, inc. (CASI)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
-8,233	-12,282	-9,669	-15,250	-8,160	-9,264	-8,756	-5,859	-3,590	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-5,047	-1,613	-2,408	-1,700	-2,673	-1,693	-3,291	-1,794	-1,702	-1,604	-2,095	-1,803	-1,596	-21,538	-1,616	-1,450	-1,308	-1,442	-1,851	-1,135	-360	-1,187	-10,463	-2,533	1,004	-1,308	-1,658	-2,596
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization for property and equipment
146	42	-63	485	139	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization for property and equipment
-	-	-	-	-	-	-	-	65	48	31	19	18	18	15	13	19	17	17	16	16	15	13	12	6	4	3	4	4	5	5	5	4	4	9	11	12
Net loss on disposal of property and equipment
0	-1	0	-0	-1	0	-5	0	0	-	-	-	-	-0	-0	-39	53	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	-48	1	55
Amortization of intangible assets
377	368	406	388	387	360	347	347	250	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction in the carrying amount of the right-of-use assets
314	-	-	-	210	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gain) loss on disposal of intangible assets
450	-	-	-	-48	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of intangible assets
-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
1,905	1,990	2,010	1,426	1,883	2,601	1,705	1,552	260	134	165	194	156	793	224	1,604	372	347	321	472	399	336	988	491	372	489	389	945	218	232	277	204	264	43	32	41	491
Acquired in-process research and development
1,081	1,118	0	5,848	0	0	0	0	552	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of investment in equity securities
15	-67	159	240	-45	253	55	101	-89	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on equity investment
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest
-	-	-	-	-	0	0	0	0	1	1	1	1	5	7	7	7	7	22	22	22	22	3	0	0	-	-	-	-	0	0	9,165	875	0	0	0	0
Change in fair value of contingent rights
-	-	-	-	-	-	-	-	-	7	16	-10	6	2	-2	5	1	-10	-35	11	6	-18	6	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
579	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	0	-23	0	-0	23	0	0	0	0	0	0	-669	669	0	0	-1,932	1,932	0	0	-2,750
Inventories
-2,533	2,129	1,892	389	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-6	-2,820	-4,927	2,489	-493	6,333	389	-155	377	-119	186	-84	17	-45	170	-92	-119	33	88	-101	102	-8	199	-143	8	-36	78	99	-51	-49	95	20	-57	-30	49	3	-93
Accounts payable
-729	124	2,519	950	407	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-522	710	20	63	55	145	-26	162	-100	82	-167	-25	240	154	26	-18	189	50	-246	-49	144	20	-92	-166	290	-38	-488	-417	46
Payable to related party
-	-	-	-	-	-2,880	2,880	0	-2,228	2,228	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-86	30	55	0	0	-	-	-	-
Accrued liabilities and other liabilities
-1,020	372	-504	539	-580	624	280	152	-287	443	-7	110	-51	88	1	2	-11	-0	-12	6	10	0	-5	5	1	13	-1	5	-5	-34	-181	61	55	-17	-32	-13	-281
Net cash used in operating activities
-4,634	-4,818	-4,748	-8,459	-5,217	-15,146	-4,092	-3,378	-5,966	-1,355	-1,571	-1,945	-1,530	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,218	-1,214	946	-905	-1,788	-2,041	462
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposal of intangible assets
450	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,363	-1,440	-1,291	-1,522	-1,489	-1,209	-1,100	-1,024	-980	-890	-713	-1,375	-1,046	-139	-	-	-	-	-	-	-	-
Proceeds from disposal of property and equipment
-	-	-	-	-	0	1	0	0	-	-	-	-	0	0	64	93	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1	55
Purchases of property and equipment
1	37	58	79	252	269	135	571	155	528	149	223	33	63	31	63	63	1	7	15	1	46	3	139	42	26	0	3	13	36	11	0	0	0	1	0	4
Acquisition of Abbreviated New Drug Applications and related items
-	-	-	-	-	2,035	0	0	18,607	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	30	-1	-7	-15	-1	-46	-238	-139	-42	-26	0	-3	-13	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
449	-7,781	-58	-19,966	-252	-2,304	-134	-571	-18,762	-528	-149	-223	-33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11	0	0	0	-1	28	50
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	10,000	0	0	0	0
Debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	683	0	0	0	0
Proceeds from sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-59	24	0	10,825	-1	0	0	1	0	1,099	53	158
Repayment of loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	757
Stock issuance costs
42	182	-0	1	7	66	110	433	211	462	0	0	0	24	5	8	57	0	0	0	0	-	-	-	-	0	0	-2	450	0	16	72	0	-	-	-	-
Proceeds from sale of common stock
1,399	182	0	0	0	1,000	36,499	20,699	29,790	23,870	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash contribution from redeemable noncontrolling interest
0	0	0	0	20,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,011	5,960	10,281	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
3,832	740	75	0	38	0	81	78	98	325	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of stock options to satisfy tax withholding obligations
251	355	0	-0	12	0	62	54	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of warrants
0	1,607	972	0	695	2,873	127	986	973	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,952	10,223	0	0	0	0	-	-	-	-	0	24	2	10,374	-	-	-	-	-	-	-	-
Net cash provided by financing activities
4,938	2,152	-820	-0	20,714	2,807	37,535	21,277	30,650	23,733	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16	-72	9,318	0	-24	1,013	-598
Effect of exchange rate change on cash and cash equivalents
-489	827	-1,383	-1,055	284	-19	-656	-999	477	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
264	-9,620	-7,011	-29,481	15,529	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	6,397	21,849	-1,720	-2,168	-1,563	2,955	5,602	4,589	8,813	-1,292	-1,529	-1,505	-1,210	-1,147	-1,262	-1,119	-932	-740	-1,351	-1,047	10,221	-762	-1,246	-1,286	10,264	-905	-1,814	-999	-85
Supplemental disclosure of cash flow information:
Interest paid
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	7
Income taxes paid
0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash financing activity:
Accrual for acquisition of in-process research and development
1,081	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant issued to placement agent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	115	0	0	0	0	-	-	-	-
Partial settlement of contingent rights derivative
-	-	-	-	-	-	-	-	-	-	-	-	-	2,047	188	1,122	1,922	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-